Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: Up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

International Journal of Clinical Practice

Volumn 66, Issue 8, 2012, Pages 731-740

  Gomis, R ^a   Owens, D R ^b   Taskinen, M R ^c   Del Prato, S ^d   Patel, S ^e   Pivovarova, A ^f   Schlosser, A ^f   Woerle, H J ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF PISA   (Italy)

^e BOEHRINGER INGELHEIM LTD   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84863982766     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02975.x     Document Type: Article

References (23)

1. Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43. (Pubitemid 44903747)
2. Turner RC, Cull CA, Frighi V, Holman RR,. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12. (Pubitemid 29254858)
3. Inzucchi SE,. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72. (Pubitemid 34256388)
4. Barnett A,. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-70. (Pubitemid 44560347)
5. Barnett AH,. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther 2011; 28: 447-59.
6. Scheen AJ,. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010; 49: 573-88.
7. Graefe-Mody U, Friedrich C, Port A, et al., Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-46.
8. Del Prato S, Barnett AH, Huisman H, et al., Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-67.
9. Taskinen MR, Rosenstock J, Tamminen I, et al., Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
10. Owens DR, Swallow R, Dugi KA, Woerle HJ,. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-61.
11. Gomis R, Espadero RM, Jones R, et al., Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-61.
12. Schlosser A, Owens D, Taskinen M-R, et al., Long-term safety and efficacy of the DPP-4 inhibitor linagliptin: data from a large 2-year study in subjects with type 2 diabetes mellitus [abstract OP-242]. Presented at: 47th Annual Meeting of the European Association for the Study of Diabetes; 2-16 September 2011; Lisbon, Portugal.
13. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-9.
14. Davidson JA,. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009; 76: S28-38.
15. Monami M, Iacomelli I, Marchionni N, Mannucci E,. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-35.
16. Elashoff M, Matveyenko AV, Gier B, et al., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-6.
17. Parks M, Rosebraugh C,. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-7.
18. Dore DD, Seeger JD, Arnold Chan K,. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-27.
19. Garg R, Chen W, Pendergrass M,. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-54.
20. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al., Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34: 369-74.
21. Schernthaner G, Barnett AH, Emser A, et al., Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 470-8.
22. Williams-Herman D, Engel SS, Round E, et al., Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
23. Rosenstock J, Niggli M, Maldonado-Lutomirsky M,. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 571-8.